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Study of Palliative Radiotherapy along with Nimorazole as hypoxic radiosensitizer in 
locally advanced head and neck squamous cell carcinoma 
Dr.Ragavendra A*, Dr.N.V.Kalaiyarasi, Dr.S.Shanmuga kumar 
Department of Radiotherapy, Madras Medical College, Chennai 
Introduction: 
Solid tumors may contain oxygen-deficient hypoxic areas and such areas may cause 
tumors to become radioresistant. Many studies in the past showed modification of tumor 
hypoxia significantly improved the loco-regional tumor control. 
Aim: 
To assess the immediate loco regional response rates of LAHNSCC with palliative 
radiotherapy along with Tab.Nimorazole; to assess the degree of symptom relief; to assess 
acute toxicity of treatment protocol. 
Materials and methods: 
30 patients presenting to our department with biopsy proven LAHNSCC (stage IV A 
with ECOG 3 and IV B with ECOG 2 or 3) from sites oropharynx, hypopharynx and larynx, 
non metastatic, ineligible to receive chemotherapy along with radiotherapy, in the age group 
of 18-70, treatment naive and willing to participate in the study were included. Patients were 
treated with hypofractionated radiotherapy 48Gy/300cGy#/3.2 weeks and Tab.Nimorazole 
1.2 gm/m² (1500 mg) daily 90 minutes before RT. The response to treatment was assessed 
after 6 weeks clinically and radiologically using RECIST criteria. The symptoms experienced 
by the patients before and after treatment were recorded using symptom assessment scale. 
The toxicities of radiation and nimorazole were recorded. 
Results: 
21 patients were in stage IV B and 9 in stage IV A. 14 among 21 showed partial 
response and others had static response in stage IV B. Among the 9 in the stage IV A, 6 had 
complete and 3 had partial responses. 20 patients showed significant (>50%) improvement in 
symptoms. None of the patients developed severe toxicities specific to Nimorazole. We 
observed grade 2 nausea and grade 1 vomiting in 4 patients and these had dose reduction for 
nimorazole. None of the patients developed rashes or flushing. None of the patients 
developed grade 4 mucositis. None developed significant haematological toxicities except for 
grade 1. 
Conclusion: 
Hypofractionated Radiotherapy along with Nimorazole demonstrated a significant 
benefit in the palliative treatment of LAHNSCC in patients with poor performance status 
without added toxicities. Yet long term studies with larger population groups are needed to 
arrive at a statistically significant conclusion. 
Key words: palliative radiotherapy, hypoxia, hypoxic modification, nimorazole. 
INTRODUCTION 
Head and neck cancers (HNC) comprise a heterogeneous group of 
malignant tumors which can arise from any of the structures cephalad to the 
clavicles. These generally do not include those arising from the brain, spinal 
cord, base of the skull, and the skin. These malignancies can arise from 
epithelium or connective tissue mesenchymal structures. In this dissertation 
we restrict our discussion to epithelial malignancies alone. For a clear 
understanding of these malignant tumors, head and neck region is 
anatomically separated into those cancers arising from the sites such as oral 
cavity, oropharynx, larynx, hypopharynx, nasopharynx, nasal cavity and 
paranasal sinuses, thyroid and major salivary glands. 
Squamous cell carcinoma is one of the most common cancers 
presenting in our country which constitutes at least 25% of the overall cancer 
burden. Around the world, squamous cell carcinoma of the head and neck 
(SCCHN) accounts for more than 5 million new cases every year. Globally it 
is the 5th most common malignant disease.  About 300,000 head and neck 
cancer patients die annually, which is a very huge burden on our community.1. 
The distressing feature in this magnitude of problem is about two thirds of the 
new cancer cases are from developing countries and many such countries are 
from Asia, where the medical facilities are still struggling to reach the people 
under poverty. Significant proportion of oral cavity cancers is reported from 
counties like Australia, India, South Africa and Western Europe2. According 
to South Asian journal of cancer, the incidence of cancer is highest in India 
among the SAARC countries3. 
Based on the present data, no single cause or mechanism is postulated 
as responsible for causation of cancer in human beings. But it is an 
established fact that the incidence and prevalence of cancer in a geographical 
area is very much influenced by the specific environmental conditions 
existing in that area as well as the life style and cultural habits and behaviour 
of that particular population. Hence the cancer trends vary from population 
groups to population groups. In our country and in other developing countries 
like South East Asia, some of the African countries and South American 
countries the incidence and prevalence of HNC is very high. On a contrary, 
the incidence of HNC is very low in the developed countries like Northern 
Europe and USA. 
Because they show a wide variation in their natural history, prognosis 
and response to treatment, Head and neck cancer is felt to be of great 
importance to the researchers and oncologists. One more reason for its 
importance is because of the physical and psychological morbidity it 
produces; and also the resulting significant burden on the family and society. 
Face is the index of soul. The organ system of Head and neck is 
designed for the most important physiological functions such as respiration, 
nutrition, language and expression, many of which are characteristic to 
mankind. Any surgery, reconstruction, toxicities of radiation and 
chemotherapy will produce a lot of alterations and compromise the normal 
physiological functions; any extensive surgery causes disfigurement and a 
diminution of quality of life. 
INDIA 
HNC represents a major public health problem in India. These cancers 
are most often related to the cultural, behavioural and life style changes of 
individuals and mostly occurs in 6th and 7th decades. The infectious diseases 
being kept under control, the incidence of HNC in India is on the rise, and its 
subsequent increased longevity of the population.  
About 200,000 new cases of head and neck cancer arise in India every 
year, of which 80,000 cases are diagnosed from oral cavity, 40000 cases from 
pharynx excluding nasopharynx and 29,000 cases from larynx. Majority of 
these cases (60%-80%) are presenting to health care centers in advanced stage 
only4. 
TAMIL NADU 
In men the single and most common cancer reported is head and neck 
cancer, as per Madras Metropolitan Tumor Registry (MMTR) data; stomach 
and lung follows it in succession. In women also the burden has increased and 
today HNC is the 4th commonly occurring cancer. 17.8% of all cancers have 
been registered in Government general hospital, Chennai alone during the 
period 2006-2008. Men suffer from HNC more commonly than women and in 
comparison it is attributable to 25.62% versus 11.35%5. 
Most of the cases present in loco regionally advanced stage and even in 
the early stage disease less than half of the patients achieve cure. The 
advanced nature of the disease carries a poor prognosis and this leads to 
uncontrolled loco-regional disease and hence its sequelae of death. Because of 
this, the 5-year survival is less than 20% even with combined modality 
treatment. 
HNC registered in Barnard institute of radiology and oncology 
constitutes a bulk of 35 to 40% of all new cases registered in a calendar year 
all over Tamilnadu. Among them, 65 to 75% of the patients present in 
advanced stages. 
 
 
 
 
 
ETIOLOGY 
Important etiological factors established in the development of SCCHN: 
1) tobacco in all forms, 
2) alcohol abuse, 
3) quid chewing, 
4) HPV-16 infection (Human Papilloma Virus), 
5) Diet and nutritional factors, 
6) Occupational hazards, 
7) Immune suppression and genetic predisposition, 
8) Oral hygiene and dental factors. 
Smoking  
Smoking was established independent risk factor for oral, pharyngeal 
and laryngeal cancers and it was the first identified one.6. In India, Tobacco 
can be used as smokeless forms such as ghutka, as quid with beetel nut 
chewing, etc. and smoke forms such as ganja, beedies, cigars, pipes, etc. All 
are responsible for the development of SCCHN. Beedi smoking is more 
hazardous than any other as it is not filtered and the contents of tar, nicotine 
are more compared to manufactured cigarettes. Also there are of different 
ways in using them like reverse smoking which is more harmful. Till date it 
was identified that Tobacco contains almost 3800 chemicals among which 62 
are established carcinogens. 
Betel quid chewing 
Betel quid consists of pieces of areca nut, slaked lime and tobacco. 
Additional substances to this are spices, cardamom, cloves, which are added 
as per the local preferences and they are called as gutkha, zarda, mawa, 
khaini. 
Quid is the most common form of tobacco abuse in India which causes 
oral cavity cancer leading from premalignant lesions mainly sub mucosal 
fibrosis and at later date invasive cancer. 
Alcohol 
Alcohol consumption has been found to increase the risk of 
development of SCCHN. The quantity, frequency, type, duration of 
consumption have all been correlated with the development of SCCHN.7 
More worser than this is tobacco smoking and alcohol together have 
synergistic and supra additive effect. There is a significant relationship with 
duration of consumption, amount, heavy and light smokers/drinkers, in the 
development of oropharyngeal/laryngeal cancer8. Landmark analysis by 
International Head and Neck Cancer Epidemiology found the population 
attributable risk (PAR) for SCCHN and concluded that PAR for tobacco or 
alcohol was 72% for HNC. Out of this 72%, 33%, 4% and 35% were due to 
tobacco alone, alcohol alone and due to combination of alcohol and tobacco 
respectively9. 
HPV 
Human papillomavirus associated HNSCC should be distinguished as a 
different disease from the usual HNSCC, since the treatment aspect will be in 
a distinct line. The important thing to be remembered is HPV positivity is 
associated with a improved response to treatment and survival benefit, which 
was independent of any treatment modality. Recent trend in the treatment, 
based on these findings is the treatment can be de-escalated to avoid 
unnecessary toxicities. But there are no randomized controlled trials to 
support this principle; at the same time still some researchers feel that 
aggressive form of combined modality treatments may represent an 
overtreatment10, 11. 
Genetic 
Researchers have found that GST gene alleles were responsible for 
determining susceptibility to head and neck carcinomas12. 
Fanconis Anemia is associated with mutations of the genes like FAA, 
FAD and FCC, lymphoid malignancy and the resulting risk of development of 
second primary in tongue, Pyriform fossa and post cricoid region13 
Bloom Syndrome is associated with mutations in helicase genes and 
they are predisposed to develop solid tumors, about 6-8% risk of getting 
tongue and larynx cancers14 
Homozygotes with ataxia telangiectasia who survive into the adulthood 
are at increased risk of developing T-cell Leukemia. These patients are 
predisposed to develop cancers of the oral cavity, Stomach, Pancreas, Breast, 
Ovary and bladder15 
Xeroderma pigmentosum manifests second primary in the oral cavity in 
addition to primary skin malignancies(14,16) 
Cowden disease (PTEN), Multiple Endocrine Neoplasia type 1 (MEN 
I) and type 2 (MEN II), Neurofibromatis Type II (NF-2) and Retinoblastoma 
(Rb) are some of the syndromes associated to primaries in head and neck. 
Diet and Nutrition 
The American Institute of Cancer Research (AICR) and World Cancer 
Research Fund (WCRF) says fruits and vegetables seem to protect against 
several cancers in the aero digestive tract and also pancreas and prostate. The 
exact extent of the protection and how it works has not yet been fully 
understood17. 
There is an entity called ‘Energy balance’ which means eating and 
drinking about the same amount of calories leading to the optimal body 
functioning. It is the main way to maintain a healthy weight. Other systems of 
medicine also talks about this. Maintaining a healthy weight is one of the 
most important ways as a protection against cancer, as we always say 
‘prevention is better than cure’. 
Plummer-Vinson syndrome: 
This syndrome representing a triad of dysphagia, iron-deficiency 
anemia and esophageal webs carries a higher risk of malignancies of upper 
digestive tract. The characteristic dysphagia occurring in this is painless and 
intermittent, limited only to solids with or without weight loss. Iron 
deficiency is thought to be the etiological factor for predisposition to 
malignancy. 
Oral hygiene and dental considerations: 
 Poor oral hygiene, ill fitting dentures and faulty restorations, and sharp 
teeth may be associated with the development of oral cavity cancers, though 
their exact etiological link is not known. Chronic trauma might be the 
possible cause for the malignant transformation of epithelial cells with 
additive effect from other carcinogens.  
Through a process called chemical carcinogenesis the microorganisms 
from dental plaque may generate nitrosating enzymes which are toxic. In 
individuals with poor oral hygiene, this carcinogen will not get diluted and 
together with the various tobacco related habits leads to the development of 
malignancy. (Shah 2003) 
HEAD AND NECK FIELD CANCERIZATION: 
The clinical evidences provided by studies such as the impact of 
tobacco and viral exposure in Head and Neck tumorigenesis, categorizing the 
distant second lesions into 2nd primary/ 2nd field tumor and the degree of 
incidence of tumors arising from the pre malignant lesions help us to gain 
knowledge on this. 
A) Impact of Tobacco and Alcohol Abuse: 
HNC has been shown to be highly associated with tobacco and alcohol 
exposure. In fact, it is estimated that 50-70% of deaths resulting from oral and 
laryngeal cancer can be attributed to tobacco smoking. The risk of developing 
HNC increases as a function of both the intensity (e.g., packs per day) and the 
duration (e.g., pack years- no of pack per year * no of years of exposure) of 
tobacco exposure and decreases gradually following cessation of tobacco 
exposure20. (Blot, W. J 1988) 
B) HPV: 
While the majority of head and neck cancers were attributable to 
tobacco and alcohol exposure, nearly 30% of them occur in nonsmokers. The 
etiologic agents or intrinsic factors responsible for head and neck cancer in 
nonsmokers are less understood. However, they may also influence the head 
and neck region in a field cancerization manner. For example, mucosa of the 
entire upper aerodigestive tract can be infected by human papillomaviruses 
(HPV), albeit in a potentially more focal fashion than that affected by tobacco 
exposure. While the reported frequency is highly variable depending on the 
detection technique, more than 50% of head and neck cancers, especially in 
the tonsil and base of tongue, have been reported to harbor (HPV). It has been 
shown that high-risk HPV16 is present in 90% of HPV-positive HNC cases 
and that the gene products of HPV 16 are reported to be especially potent with 
regard to interfering with cell cycle regulation, altering cellular response to 
injury, promoting genomic instability, and facilitating immortalization. These 
findings suggest that HPV 16 can facilitate the acquisition of genetic events 
leading to development of tumors of head and neck region or can act in 
combination with other etiological agents. (Li S L, 1992). 
 
C)  Second Primary Tumor 
The incidence of second primary tumor has started increasing and it 
was reported as high as 10%. It could be either synchronous or metachronous; 
analysis of metachronous lesions show the frequency of second primary 
tumor (SPT), a third primary tumor (TT), and a fourth primary tumor (QT) as 
3 to 5%, 0.5% and 0.3% respectively. The second primary tumor behaves in 
an aggressive manner and is much more resistant to treatment, and 
metastasizes early, so that it emphasizes the importance of a more aggressive 
treatment strategy. (Mehdi I 2010) 
PRECANCEROUS LESIONS: 
Leukoplakia 
It is the most common precancerous lesion in head and neck. It is 
treated by excision. The estimated 10-yr risk of malignant transformation for 
leukoplakia is about 10%, and this goes even upto 40% if there is advanced 
histology pattern within. More important than this is only half of these 
patients developed cancer in the site of leukoplakia (Silvermann S Jr 
1984). 
Erythroplakia 
It is more dangerous because of higher risk of malignant transformation 
than leukoplakia18. It has been found in studies that 51% of the erythroplakia 
patients had invasive cancer; 40% had carcinoma in situ; and 9% had mild or 
moderate dysplasia. 
Submucosal fibrosis 
Malignant transformation is very compared to other two. Recently it is 
the main risk factor in the increase in incidence of oral cavity cancers in 
young individuals (< 35 years) in India. 
ANATOMY 
For the benefit of staging, stratifying treatment protocols and 
comparing the results of all modalities of treatment, it is must to divide the 
head and neck epithelial regions into sites such as oropharynx, hypopharynx 
and larynx, which were included in this study and oral cavity, nasopharynx 
and nasal cavity and paranasal sinuses which were not. 
Oral cavity: 
It is further subdivided into subsites such as lips, anterior 2/3rd tongue, 
buccal mucosa, alveolar ridge, hard palate, retro molar trigone and floor of 
mouth. 
 
 
 
Figure -1: Head and neck anatomy 
 
Oropharynx:  
The oropharynx is the postero inferior continuation of the oral cavity. 
From above downwards, it extends from the superior surface of soft palate to 
the superior surface of the hyoid bone or vallecula. The oropharynx contains 
base of tongue, soft palate and uvula, tonsillar pillars- anterior and posterior. 
It also contains the glossotonsillar sulci, the pharyngeal tonsils, and the lateral 
and posterior pharyngeal walls. 
Base of tongue: It is bounded anteriorly by circumvallate papillae, its 
lateral limit is the glossotonsillar sulci, and posterior limit is the epiglottis. 
The vallecula is a strip of mucosa that is in the transition from the base of the 
tongue to the epiglottis. But it is considered a part of the base of the tongue. 
The muscles of the base of tongue are continuous with the anterior two third 
of the tongue.  
Tonsillar fossa: Its anterior limit is anterior tonsillar pillar; posterior 
limit is posterior tonsillar pillar; inferiorly bounded by glossotonsillar sulcus 
and pharyngoepiglottic fold. Laterally the tonsillar region is bounded by the 
pharyngeal constrictor muscle and its fascia, the mandible, and the lateral 
pharyngeal space. Glossotonsillar sulcus separates it from base of tongue. 
Beneath the mucous membrane of the sulcus the styloglossal muscle and the 
stylohyoid ligament are present. 
Soft palate: It is a thin, mobile muscle complex .The epithelium of oral 
side of the soft palate is squamous while the epithelium of the nasopharyngeal 
surface is respiratory type. It is continuous laterally with the tonsillar pillars.  
Larynx 
The larynx is composed of many cartilages connected by ligaments and 
muscles. It is divided on anatomic considerations into the supraglottic, glottic, 
and subglottic regions.  
Supraglottis: Contains of the epiglottis (infra and supra hyoid), false 
vocal cords, ventricles, aryepiglottic folds and arytenoids. The arytenoids are 
cartilages which articulate on the cricoid. 
Glottis: It contains the true vocal cords and includes their superior and 
inferior surfaces and their anterior and posterior commissures. 
Subglottis: The subglottis is 2 cm long. It extends from five 
millimetres below the free edge of true vocal cords to the inferior border of 
cricoid cartilage. 
The preepiglottic space is a potential space bounded by the epiglottis 
posteriorly, the hyoepiglottic ligament and vallecula superiorly, and the 
thyroid cartilage and thyrohyoid membrane anteriorly and laterally. It can be 
seen as a low-density area on a computed tomography.  
The supraglottic structures have a moderate to rich lymphatic supply. 
The lymphatic vessels pass via pre-epiglottic space and thyrohyoid membrane 
to the level II group. Some trunks drain directly to level III or IV group. 
Lymphatics capillaries are absent in the true vocal cords; hence, if any 
lymphnode spread from carcinoma glottis, is usually due to tumor extension 
to supraglottis or sub glottis. The sub glottis has few lymphatic capillaries.  
The lymphatic vessels pass via thyrocricoid membrane to pretracheal 
nodes in the region of isthmus of thyroid, or the trunks may drain into the 
level IV nodes. The pretracheal nodes are midline and, their salient feature is 
even when clinically positive, are 1 cm or less in diameter. 
Posterior drainage of subglottis to the level IV nodes is through the 
cricotracheal membrane. 
Hypopharynx 
The posterior pharyngeal wall extends from base of skull low down to 
lower border of cricoids cartilage. The lateral pharyngeal wall is a narrow 
strip of mucosa that lies behind the posterior tonsillar pillar in the oropharynx, 
and then continues down into the hypopharynx. Here it forms the lateral wall 
of the pyriform fossa.  
The pyriform fossa is made up of three walls: the anterior, medial, and 
lateral (there is no posterior wall). The pyriform sinus tapers inferiorly to the 
apex and usually terminates variably at a level between the superior and 
inferior borders of the cricoid cartilage. Superior limit of pyriform sinus is 
opposite the hyoid. The thyrohyoid membrane is lateral to the upper portion 
of the pyriform sinus, and the thyroid cartilage, cricothyroid membrane, and 
cricoid cartilage are lateral to the lower portion. Superiorlaryngeal nerve 
(internal branch), a branch of vagus, lies under the mucous membrane on the 
anterolateral wall of the pyriform fossa. The auricular branch is sensory to the 
skin of back of the pinna and the posterior wall of the external auditory canal. 
The postcricoid pharynx is funnel shaped to direct food into the gullet. 
The superior margin begins just below the arytenoids. The anterior wall lies 
behind the cricoid cartilage and is the posterior wall of lower larynx. The 
posterior wall is a continuation of hypopharyngeal walls. Recurrent laryngeal 
nerve lies between the lateral wall and the deep surface of the thyroid gland. 
 
PATHOLOGY 
Most of the head and neck malignant neoplasms arise from the 
epithelium and are squamous cell carcinoma. There are few variants of this 
such as, lymphoepithelioma, spindle cell, basaloid and verrucous carcinoma. 
In general, poorly differentiated cancers are more prone for the regional 
metastases, so prognosis is poor. Pathological grade is not a consistent 
predictor of prognosis. Features that predict aggressive behaviour and poor 
prognosis include perineural spread, lymphatic invasion and extracapsular 
extension (ECE) of lymphnode. 
Morphologically, four types of growth patterns are recognized.  
Ulcerative: It is the most commonly occurring type. It is oval or round 
ulcer that is friable in nature. 
Infiltrative: Ulcerative lesions extending deeply into underlying 
tissues become an infiltrative growth. 
Exophytic: It usually grows superficially and metastases occur at later 
stages when compared to the other types. It looks like an area of thickened 
epithelium. 
Verrucous cancer: It is a rare variety, commonly occurs in older age 
group. Its occurrence is associated with poor oral hygiene and ill-fitting 
dentures. It is bulky, warty and raised fungating lesion. It never gives rise to 
metastases. 
Other tumor types: 
Other less common histological types are  
Sarcomatoid carcinoma, Mucoepidermoid carcinoma, Adenoid cystic 
carcinoma, Adeno carcinoma, Melanoma, Ameloblastoma, Mucosal 
melanoma, Small cell undifferentiated cancer, Esthesio neuroblastoma 
(Olfactory neuroblastoma), Kaposi’s sarcoma, Lympho epithelioma, 
Hodgkin’s lymphoma and Nonhodgkin’s lymphoma 
Grades 
Grade 1: well differentiation 
Grade 2: moderate differentiation 
Grade 3: poor differentiation 
Grade 4: undifferentiation 
Figure – 2: Grade 1, 2 and 3 squamous cell carcinoma  
 
 
PATTERNS OF SPREAD 
Spread is dictated by local anatomy and varies by each anatomical site. 
By direct spread muscle is invaded and spread along the fascial planes to 
involve adjacent soft tissue structures also occurred. 
Tumor may attach to periosteum or perichondrium but involvement of 
bone and cartilage is a late event. Bone or cartilage act as barriers to spread 
and its invasion is indicative of a biologic aggressiveness of SCCHN. Slow 
 
growing neoplasms of the oral cavity may produce a smooth pressure defect 
of the underlying bone without actual bony erosion. 
Spread of tumor into space allows superior or inferior spread from base 
of skull to lower neck. 
Perineural spread is observed in muco epidermoid carcinoma which 
predicts a poor locoregional control rate. Tumors with perineural spread may 
track along the nerve to base of skull, central nervous system and also 
peripherally which may lead to neurological symptoms. Invasion of the 
vascular space lead to the development of regional and distant metastases. 
Lymphatic spread 
Lymphatic involvement depends on the staging, histology, grade and 
site of the tumor and also the presence of vascular space invasion and the 
density of lymphatics. By studying the occurrence of node positive cases by 
elective neck dissection or by determining the probability of regional 
recurrence, the risk of sub clinical disease in a clinically negative neck can be 
obtained.  
The relative incidence of clinically positive nodes is determined by the 
anatomic site of primary and T stage. Well lateralized lesion will spreads to 
ipsilateral neck. Midline lesions spread to both side; carcinoma of tongue base 
and nasopharynx will involve both sides of neck even when it is situated well 
laterally. 
Figure -3: Lymph Node Levels in the Neck 
 
 
Patients with large or multiple clinically positive ipsilateral nodes are at risk 
of developing contralateral disease. Disturbance and obstruction of the 
lymphatic pathways by surgery or Radiotherapy shunts the lymphatic flow to 
the opposite side. Contralateral metastases from a well lateralized lesions 
most commonly involves the level II node; sometimes may be bypassed the 
level II and involves level III or level IV. 
 
Table – 1: Lymphatic drainage of head and neck 
Ia Submental group 
Ib Submandibular group 
II Upper deep cervical  group 
III Mid deep cervical group 
IV 
Lower deep cervical group     
(transverse cervical) 
V Spinal accessory chain lymph nodes 
VI 
Prelaryngeal, pretracheal, 
paratracheal group 
VII Superior mediastinal lymph nodes 
 
The incidence of retropharyngeal adenopathy is based on the primary 
site and presence of clinically involved nodes. Involvement of lymph node 
levels is predictive of the primary site. Lip and oral cavity tumors spread to 
level I initially. Laryngeal and pharyngeal cancers involve levels II and III. 
 
Distant spread: (haematogenous spread) 
Risk of distant metastases is related to neck stage (N stage), lymph 
node location and site of primary. Risk is less than 10% for N0 or N1 neck 
and 30% for N3 and N1 or N2 below thyroid notch. Hypopharynx and 
oropharynx carcinomas give distant metastases more commonly than oral 
cavity. Lung is the commonly involving organ in metastatic SCCHN (50%), 
next coming are liver and bone. 
HISTORY, PHYSICAL EXAMINATION AND DIAGNOSTIC 
WORK-UP 
Detailed clinical history of the patient including the history of usage of 
tobacco, alcohol, oral sex, and other environmental exposures which are 
mentioned in etiological risk factors should be taken. Patient with symptoms 
suggestive of malignancy of upper aerodigestive tract of more than two weeks 
duration or with an asymptomatic neck mass should be evaluated further 
carefully. 
PHYSICAL EXAMINATION  
Thorough physical examination we can find even the early lesions of 
the aerodigestive tract and also the multiple primaries which are common in 
upper aerodigestive tract. This will also indicate the severity and the duration 
of the disease.  
Physical examination should be done in a systematic manner so that 
any point is not going to be missed. Frequently overlooked part of the 
examination like searching for ulcers, nodules, pigmented and other suspected 
lesions should be done carefully.  
Cranial nerve examination is must for all patients of head and neck 
tumor or mass. Any discharge, bleeding and drainage from eyes, nose and ear 
to be looked for. 
Examination of the oral cavity should be done completely. Looking for 
halitosis and Trismus is must. Bimanual palpation of the floor of mouth, 
tongue, buccal mucosa should be done with one finger inside the mouth and 
other outside the mouth. Mandible is to be palpated for involvement; any 
tenderness, thickening, discharge, sinuses etc. to be noted and biopsy of the 
suspected lesions are to be taken. 
Nose: External nose, anterior nares, alae and vestibule should be 
carefully examined.  
Neck: Neck examination is to be done systematically to look for the 
location of any mass. Palpation is an important step in the examination of 
neck.  Mass and the nodes are palpated between the thumb and index or 
middle finger. 
The location, size, consistency, fixity and tenderness of the node are to 
be examined. 
Posterior Rhinoscopy:- To see choanae, entire nasopharynx .  
Anterior rhinoscopy:- To see the vestibule, nasal septum, lateral wall 
and floor of the nasal cavity.  
Indirect Laryngoscopy: For examining the Base of the tongue, 
Vallecula, hypopharynx and the larynx. Inspection and mobility of the vocal 
cords is to be evaluated. This provides an overall picture of the mobility and 
asymmetry indicating the presence of an occult tumor.  
Direct Laryngoscope:- Thorough visualization of the nasal cavity, 
nasopharynx, oropharynx, hypopharynx and larynx can be done and pooling 
of secretions to be noted. Individual subsites also to be looked into for any 
doubtful lesions.  
Endoscopy:- Because of the field cancerisation patient with Head and 
neck malignancy will have a 5% of chance of Synchronous primary that is 
SCCHN, lung or oesophagus. Laryngoscopy(direct), oesophagoscopy and 
bronchoscopy (Triple endoscopy)  to be done in all patients with an unknown 
primary  and in a known primary of HNC and doubtful lesions are biopsied. 
These can also provide details about the extension of disease.  
 
DIAGNOSTIC IMAGING  
Chest X-ray:– to see for any pulmonary metastases or a second 
primary. 
Orthopantomogram:- To look for involvement of bone in oral cavity 
lesion.  
USG: It can pick up few non palpable nodes; can provide information 
on whether a node is malignant or benign; can differentiate a thyroid gland 
mass from lymph nodal mass. 
CT scan 
It delineates the extent of the tumor (both primary and secondary) and 
can differentiate the solid from cystic lesion.  
The site of an unknown primary with secondary neck node can be 
identified by CT scans of chest, abdomen and pelvis. It has advantage over 
MRI in detecting bony erosions. With its high spatial resolution fat, muscle, 
bone and other soft tissues are easily identified. 
Dynamic contrast CT [DCC]: With the use of less contrast agent, it is 
able to differentiate blood vessels from malignant mass and lymph nodes. 
Spiral CT: It is faster than DCC and it has the capacity for 
multiplannar reconstruction without compromising on the quality of scan. 
MRI: It gives information about the size, location and the extent of the 
tumor accurately. Gadolinium enhanced MRI is very useful than CT for 
imaging nasopharyngeal and oropharyngeal carcinoma. Main disadvantage is 
movement artifact particularly in larynx and hypopharyngeal carcinomas. 
STAGING 
The staging for the primary lesions (T) is done by using   The 
American Joint Committee on Cancer (AJCC) (2010). The AJCC (2010) neck 
staging (N) is common to all head and neck sites, except the nasopharynx19. 
T staging is done purely depending on the individual site. But N staging 
remains common for all. The size of the node (≤3cm, 3-≤6cm, >6cm), 
whether ipsilateral, contralateral or bilateral, should be taken into account for 
N staging. The level of the involved lymph node is also considered in 
nasopharyngeal carcinoma staging. In general, the level of lymph nodal 
involvement helps in aiding the plan for treating elective lymph nodes. 
PROGNOSTIC FACTORS 
Neck node involvement (any stage) is the single most important 
prognostic factor in determining the survival of a HNC patient (besides tumor 
status). 
Neck node involvement reduces the 5 year survival rate by 50%. 
Nodal size (N2 or N3) and extra capsular extension are distinct 
prognostic features. The risk of neck failure and poor survival are fairly high. 
Multiple lymph node involvement or contralateral nodal metastases 
denote a poor treatment outcome. 
TREATMENT OVERVIEW 
For practical purposes, SCCHN can be divided into 3 clinical stages:  
1) early disease 
2) locoregionally advanced disease 
3) Metastatic/recurrent disease. 
Of these 50-60% is locally advanced at presentation. Treatment 
approaches for each stage vary. 
EARLY STAGE DISEASE  
Usually single modality treatment with either Surgery or Radiotherapy 
provides comparable and efficacious locoregional control and survival results. 
Surgery: 
Surgical resectability of a head and neck cancer is assessed by a 
multidisciplinary team. An adequate margin of 1.5 cm to 2cm is required to 
obtain a clear frozen section. Any suspected margin of < 2 cm has to be 
examined by a frozen section. A clear margin and close margin can be defined 
as a distance of ≥ 5 mm and <5mm from the resected margin to the invasive 
tumor, respectively. Primary is usually approached through trans oral, 
transcervical routes or, through mandibulectomy. 
Reconstruction is done by using skin graft, free tissue transfer, regional 
flap, or by primary closure. Reconstructed area should functionally and 
cosmetically resemble the resected tissue. 
Neck dissection: 
Elective neck dissection is done in clinically node negative neck. 
Therapeutic neck dissection is done in clinically apparent nodal disease. 
Based on the clinical, radiological and preoperative finding, therapeutic 
dissections may be either selective or a comprehensive neck dissection. 
Tumors approaching midline or tumors with bilateral lymphatic drainage like 
base of tongue, palate, and supraglottis should undergo dissection in both 
sides of neck. 
Radiotherapy: 
Primary disease and involved neck nodes are to be treated by 66 to 70 
Gy of radiotherapy in conventional 2 Gy fractions. Low to intermediate risk 
lymph nodes are to be treated electively between 44 and 60 Gy. Advanced 
tumor stage, depth of invasion, perineural invasion, multiple node positivity, 
vascular invasion and lymphatic invasion require postoperative radiotherapy. 
Post operative chemo radiotherapy is indicated when there is extra capsular 
extension and positive margins. Postoperative radiotherapy is usually 
administered in 6 weeks or less.  Radiation may be delivered either in 
conventional or altered fractionation. 
Surgery Vs Radiotherapy 
The advantages of surgery over radiotherapy are one time procedure, 
limited amount of tissue is exposed to treatment and shorter hospital stay. 
Also disadvantage of radiation like acute and late toxicity can be avoided and 
radiation can be reserved for salvage purposes and second primaries. The 
advantage of radiation therapy is organ preservation and thereby function 
preservation.  
LOCOREGIONALLY ADVANCED CANCERS 
Aggressive multimodality treatment is needed to achieve cure in these 
patients. Therapy for locally advanced SCCHN has the major goals of 
eradicating locoregional disease, treating distant micrometastases, preserving 
organ function, and minimizing toxicities. 
In the past, 5 year survival for loco regionally advanced cancer was 
only forty percent (ten to thirty percent for patients with stage IV A and IV B 
tumors). Most of the patients developed recurrence due to loco regional 
failure. Any treatment which produces good locoregional control is the best 
one. Altered fractionation schedules have also been studied clinically. Even 
with the best possible modification of RT regimens, only a 50% to 70% local 
control rate and 30% to 40% Disease Free Survival (DFS) was achieved21. 
 Hence multimodality treatment is necessary to achieve good 
locoregional control. 50% to 60% of locoregionally advanced cancer patients 
develop locoregional recurrence within two years even after surgery, 
radiotherapy, or both and 20% - 30% of patients  landed in distant metastases. 
So, chemotherapy was investigated to maximize the response along with 
radiotherapy, either as induction, concurrent or adjuvant21. 
Induction chemotherapy 
Overall response rate of induction chemotherapy using cisplatin and 
5FU that was shown in various trials was complete response in 20 to 30%. It 
also decreased the occurrence of distant metastasis because of the early effect 
on micro metastasis in the circulation. But induction chemotherapy failed to 
show any survival benefit. The recent phase III randomised trial (DeCIDE 
trial) which using docetaxel, cisplatin and 5FU as an induction chemotherapy 
followed by concurrent chemo radiation also failed to show any survival 
benefit when compared to concurrent chemo radiation22. 
 
Concurrent chemo radiation 
Concurrent chemoirradiation has shown clinically significant benefit 
with better locoregional control as well as survival benefit. During the past 2 
decades definitive concurrent chemoirradiation has shown to improve survival 
and organ preservation in locally advanced Head and Neck Cancer23. Recent 
meta-analysis reveals an survival benefit (absolute) of 4.5% for 
chemoirradiation (neoadjuvant, concurrent, adjuvant chemoradiation) in 
SCCHN, and 6.5% for concurrent chemoradiation over RT alone24. The 
advantage of the adding chemotherapy to historical treatment is same in all 
sub sites of SCCHN25. Concurrent platinum based chemoradiation regimens 
have demonstrated improved disease control rates compared to those obtained 
using radiotherapy alone and is the most commonly used chemotherapeutic 
agent in clinical use24, with manageable toxicity. So at present the standard of 
care in patients with locally advanced and unresectable head and neck cancer 
is concurrent chemo radiation using single agent high dose cisplatin. 
Increased toxicity is noticed in combination chemotherapy group. The 
purpose of adding chemotherapy to radiation is to enhance the effect of 
radiation. So it is important to complete the radiation therapy within the 
scheduled time. It is not good to interrupt radiation in between because of 
acute toxicity of combination chemotherapeutic agents. So single agent 
chemotherapy is the preferred option. 
Adjuvant chemotherapy 
The use of adjuvant chemotherapy has a theoretical benefit of 
eradicating the sub clinical disease left behind after chemo radiation. The 
increased sensitivity of minimal residual disease to anticancer drugs has been 
shown by cell cycle and growth fraction studies. It is also postulated that 
adjuvant chemotherapy sterilizes the micro metastasis present in the 
circulation and thereby prevent distal recurrence rate and improve overall 
survival rate. Unfortunately these theoretical benefits are not proved by any 
randomised control trials. So its use is far from definitive. 
PALLIATION 
Majority of the patients presenting to the clinicians come in 
locoregionaly advanced stage, in our country and these cases are found to be 
unresectable and also not fit for any form of curative treatment. Also many 
patients presenting in stage III will have poor performance scores. These 
patients will not tolerate curative treatment. Few patients presenting in older 
ages also fall under the same category. These patients will be benefitted with 
palliative radiation and supportive care. 
PALLIATIVE RADIOTHERAPY (PRT) 
Most of the cancer patients, in fact all, have many distressing 
symptoms to be addressed with or to be palliated. Some of the important 
symptoms are pain, dysphagia, odynophagia, earache, difficulty in speech, 
trismus, bleeding from the tumor site, respiratory difficulty, stridor, etc. The 
ideal method of palliative treatment should be like this. It should produce the 
best possible symptom relief and good quality of life to the patient at the same 
time with least possible side effects and toxicities. 
This palliation can be achieved with either palliative radiotherapy alone 
or in combination with other agents such as weekly chemotherapy, 
metronomic chemotherapy, targeted agents or hypoxia modifying agents. 
Palliative radiotherapy (PRT) carries the advantage of effective 
palliation and good QOL in advanced and unresectable SCCHN26; also a 
significant amount of cancer care across the world is constituted by PRT. But, 
looking into the literature, there are very few studies about Palliative 
radiotherapy in HNC. Especially for palliative RT, because the patients 
completing the treatment protocol were very less and also poor accrual to 
prospective trials the assessment of outcome becomes difficult. And also in 
our country the personnel and radiation equipments are very much limited 
which led to delay in treating the patients with radiotherapy27. Because of this, 
the comparison of the trials which are available in the literature on 
radiobiological aspect is not a possibility and so is the toxicities and the 
leading QOL outcome obtained. Severe toxicities both early and late, due to 
radiotherapy should be avoided when treatment is aimed for palliation. And 
hence the treatment protocol should be individualised and the patients are 
treated as per the department protocols. Multiple factors such as performance 
status, comorbidities, patient preference, etc. should be considered while 
decision making. 
Recommended PRT schedules were the following 
50 Gy in 20 # (fractions) over 5 weeks 
30 Gy in 10 # over 2 weeks 
30 Gy in 5 #, 2 # per week +/- 6Gy boost 
37.5 Gy in 15 # over 3 weeks 
3.125 Gy * 16# over 3.2 weeks (Christie Scheme) 
3.7 Gy twice daily for 2 consecutive days, repeated after 4 weeks 
(RTOG 8502 regimen, QUAD-SHOT) 
3 Gy twice daily, day 1 and day 3, repeated every 2 weeks for 4 cycles 
24 Gy in 3#, 0-7-21 schedule 
When treating an end stage patient with limited prognosis and survival, 
more hypofractionated schedule can be considered. 
According to the current guidelines, the benefit of curative intent 
treatment should be given even to patients with an advanced SCCHN also 
taking into consideration the recent advancements in treatment. 
Still few factors can be considered about patient’s selection for 
palliative intent treatment alone. 
1) fixed, unresectable  and inoperable tumors (primary and secondary) 
2) very advanced, incurable loco-regional cancer with poor general 
condition and medical comorbidities; 
3)  metastatic disease and patients with limited expected survival. 
BEST SUPPORTIVE CARE 
The treatment provided for cancer apart from altering the disease 
process, can affect the patient’s physical, psychosocial and cognitive health, 
etc. And the additional steps taken to improve them along with the cancer- 
specific treatment are collectively called supportive care. In few 
circumstances such as incurable disease post treatment, the only possible way 
left behind for the benefit of the patient is Best Supportive Care.  
Best supportive care includes28  
1) The management of pain, vomiting, anemia (due to cancer and 
cancer treatment), fatigue and distress 
2) Prevention and treatment of infections due to cancer. 
3) Palliative care and nutrition support. 
Very advanced head and neck diseases can be any of the following29: 
1) Locoregionally advanced disease, newly diagnosed 
2) Unresectable nodal disease, newly diagnosed 
3) Persistent or recurrent tumors 
4) Metastatic disease newly diagnosed or post treatment 
5) Patients not fit for surgery 
While deciding the treatment options for these advanced and 
unresectable cases the Eastern Cooperative Oncology Group (ECOG) status 
should be taken into consideration. For patients with ECOG 0 - 2 and 
treatment naive without metastatic disease, concurrent chemoradiation with 
curative intent can be given. Best supportive care with Palliative RT is the 
option for patients with ECOG 3. For ECOG 4, only best supportive care is 
the possibility. Patient’s preference to decide treatment option should also be 
taken into account. Early referral to hospice care should also be considered 
for ECOG 3 and 4 patients, post treatment recurrence and incurable cases. 
 
 
REVIEW OF LITERATURE 
Palliative radiotherapy trials: 
From a large study of the past, it was observed that PRT neither 
improves survival, nor positively impacts on QOL of patients with SCCHN30. 
Further studies are contradictory to this observation. Eventhough there is no 
large randomized controlled trials to show high level of evidence for using 
PRT in head and neck cancers, a general conclusion can be obtained from 
several retrospective studies (31.32.33) case-control studies (34, 35) and single arm 
prospective studies (36, 37, 38, 39, 40) and they confirm that palliative treatment is 
associated with an improved outcome at least in the locoregional and 
symptom control. 
Lok BH et al.,(2015)41 reported on the results of palliative RT using 
RTOG 8502 regimen that is popularly known as QUAD-SHOT (3.7Gy twice 
daily over 2 consecutive days repeated after 4week interval). 37% patients 
completed atleast 3 cycles of RT. They recorded a palliative response in 65% 
of patients. Median survival was 5.67 months. Grade 3 toxicity was observed 
in 5% of patients only. Those with palliative response are those who received 
more number of RT cycles. Palliative response, good PS and more number of 
RT cycles are the independent predictors of survival. 
Nguyen et al.,(2015)42 treated advanced HNSCC patients using 
hypofractionated regimen named as "0-7-21", which treated patients with 
24 Gy in three fractions. Among 110 patients, complete response for 
symptoms and tumour size was seen in 40% and 31%, partial response was 
seen in 42% and 50%, respectively; stable disease was seen in 15%. Also 
there was a median 6-month OS of 51% and 39% PFS within the irradiated 
field. They found that advanced TNM stage resulted in a poorer tumour 
response, significantly. 
Monnier et al.,(2013)43 reported on 78 patients treated with palliative 
radiotherapy using the IHF2SQ regimen  (Irradiation HypoFractionnée 2 
Séances Quotidiennes). Patients were treated with 3 Gy BD per day (days 
1 and 3), during the week 1, 3, 5 and 7 of treatment. All patients were fit to 
receive concurrent platinum-based chemotherapy; Tolerance was excellent. 
They observed a complete or partial response in 41% of patients. A very 
excellent median OS of around 13 months and median PFS of about 11 
months were observed. One-year OS, specific survival (SS), and PFS were 
58%, 71%, 51.5%, respectively.  
Erkal HS et al.,(2001) 31 studied retrospectively, the results of 
palliative RT to 40 cases of  unknown primary with advanced neck node, with 
30 Gray in 10 fractions over 2 weeks  and 20 Gray in 2 fractions with one 
week  break in between. That resulted in a good one year local control of 
77%, along with a 68% improvement in symptom relief. Hence higher doses 
of palliative RT were associated with better outcomes. 
Carvalho et al.,(2000)35.studied on patients with advanced HNC who 
received treatment and those who did not receive any treatment until their 
death. They reported on the survival rates of the untreated group and the 
treated groups and found a significant difference between them. Also this 
difference was significant and independent of any type of treatment received 
or the tumor response obtained. 
Paris KJ et al.,(1993)36 conducted a palliative RT study which has 
used fractionated radiotherapy of 370 cGy per fraction given 2 times daily for 
2 consecutive days, totally 4 fractions, which was repeated every three to four 
weeks achieving a total dose of 42 Gray over a period of 9 weeks. Good 
palliation was reported in 33 of 37 patients with tolerable acute toxicity. They 
achieved a mean survival of 4.5 months. 
Ghoshal S et al., 38 (2004) treated 25 advanced SCCHN patients with 
short course palliative radiotherapy of 30 Gy in 10 fractions over 2 weeks. 11-
point numerical symptom assessment scale was used to assess baseline 
symptoms. After 1-month of PRT, >50% symptomatic relief was seen in all 
22 patients with pain and more than 90% of the patients with swallowing 
difficulty, respiratory distress and insomnia. 60% patients were relieved of 
cough. The median duration of symptom relief achieved was 3 months. A 
point to be noted was none developed grade 3 toxicity. 
 
Evidence for the presence of Hypoxia in solid tumor: 
Tumour hypoxia in human neoplasms was proved with histologic 
evidence and was first reported in 1955. Later on, direct measurement by 
microelectrodes within the tumor has shown much heterogeneity in oxygen 
concentrations. Researchers have found a low oxygen concentration is 
associated with poor locoregional control by either by RT or chemotherapy. 
These earlier findings along with the recent results of nuclear imaging studies 
using radiolabelled misonidazole, provide strong evidence for the presence of 
tumour hypoxia. These findings influence not only RT but also any treatment 
outcome. (Lee DJ et al. 1996) 
Moulder JE et al.,(1984)44 reviewed determinations of hypoxic 
fraction in 42 tumor systems. From these, they found that radiobiologically 
hypoxic cells appear to be present in most of the macroscopic solid rodent 
tumors. Also the hypoxic fraction increases as the tumor size increases; but 
the dependence of hypoxic fraction on tumor size at macroscopic sizes was 
not well established. Few factors that may influence the hypoxic fraction were 
the site of tumor implantation, the use of anesthesia, and certain host 
characteristics. Also there was a correlation between the hypoxic fraction, the 
tumor growth rate, transplantation history and the histology. Their final 
conclusion was that the hypoxic cells are present in solid tumors in rodents 
and also shows no evidence that hypoxic cells should not be present in 
human tumors. 
It has been shown from many preclinical studies that solid tumors 
may contain oxygen-deficient areas known as hypoxic areas and because 
of these cells, tumors may become radioresistant. Hence identification of 
hypoxic cells in human tumors has become important and this can be 
accomplished with the use of new imaging and physiologic techniques. Also 
there existed a considerable heterogeneity among individual tumors 
(Overgaard 2007)45. 
There are evidences to conclude that a high level of hypoxia in solid 
tumors has a direct link with adverse prognostication in the evolution of a 
malignant tumor, especially after treatment. The lack of oxygen in the blood 
has been correlated with poor tumor response to treatment (32, 33). This 
resistance can be explained on the radiobiological effects of hypoxia. 
Hypoxia is also a marker of aggressive tumor phenotype and it is blamed 
for the resulting poor prognosis and high likelihood of recurrence after 
surgery (34, 35). Furthermore, hypoxia may be responsible for tumor resistance 
to some oncological agents (36). 
Hypoxia is a common phenomenon in HNSCC and increases resistance 
to chemotherapy and radiotherapy. Quantification of hypoxia with PET has 
been attempted and it is used for evaluating the extent of benefit of using 
radiosensitizing drugs. F18-FDG PET-CT is the most commonly used 
investigation for monitoring response to treatment in HNSCC. Few other PET 
radiopharmaceuticals have been discovered and they have a role in assessing 
the response when biological agents such as EGFR inhibitors or VEGF 
inhibitors are used (37). 
There are radiopharmaceuticals such as 18F-Fluoromisonidazole 
that selectively accumulate in the hypoxic tissue, with minimal uptake in 
well oxygenated normal tissues. This tracer compound provides several 
advantages such as, the biological characterization of head and neck tumors 
prior to radiotherapy, and hence gives an idea about the prognostic 
information in response to treatment (38). This characterization leads to an 
advantage of using more specific treatment, in addition to radiotherapy, when 
tumor hypoxia is found in molecular therapy using PET-CT (38) 
THE OXYGEN EFFECT: 
Ionizing radiation produces free radicals which lead to cell death by 
causing single and double strand breaks. Oxidation is the process involved in 
fixing this damage. Molecular oxygen can react with these free radicals to 
produce many downstream molecules which are highly lethal to the cell. But 
when there is hypoxia within the tumor cells this beneficial effect will not 
occur. Oxygenated cells respond to ionizing radiation 2.5 times more than the 
hypoxic cells. 
HYPOXIA AND HYPOXIC MODIFICATIONS: 
Several strategies46 have been putforth by the researchers to modify and 
target hypoxia related therapeutic resistance, such as  
1. Enhancing the oxygen delivery, by using hyperbaric oxygen or 
cargogen breathing, ARCON (accelerated radiotherapy with carbogen and 
nicotinamide) treatment, 
2. Hypoxic radiosensitizers, by using misonidazole and nimorazole and 
3. Hypoxic cytotoxin, such as tirapazamine. 
G.E.Adams et al. (1979)47 studied on nitroaromatic and 
nitroheterocyclic compounds that can be used as “radiosensitizers”. They 
tested these compounds for their cell kill efficacy toward hypoxic Chinese 
hamster cells in vitro. They found a directly propotional correlation between 
the cytotoxicity and the resultant electron affinity. One important observation 
is that Non-nitro-containing compounds of similar electron affinities 
(such as quinones) eventhough acted as radiosensitizers, did not show this 
specific toxicity toward hypoxic cells. This observation tells that the 
presence of a nitro group is important for a compound to produce the hypoxic 
cell toxicity. 
R.J.Knox et al., (1981)48 studied on the various compounds that act as 
radiosensitizers. Since the mechanism of producing the desired 
cytotoxicity is identical in each case (viz. DNA damage) it shows a 
directly propotional correlation between different rates of reduction of 
the drugs, and their relative electron affinity. It has been established from 
the previous studies that the nitroimidazoles in hypoxic cells had good 
metabolic reduction rates. Olive (1979a, 1980) studied on this and showed a 
correlation with electron affinity and electrolytic reduction at constant 
potential. The results of these studies support their hypothesis that the 
cytotoxic mechanism of action of reduced nitroimidazoles is very similar 
in hypoxic mammalian cells, bacteria and protozoa. 
A meta-analysis of 50 randomized trials treated more than 7000 
patients with this hypoxic modification. It resulted in improvement in the 
loco-regional tumor control after radiotherapy with an odds ratio of 1.17. 
Site wise categorization showed an improved response in head and neck and 
to a lesser extent in bladder tumors was responsible for the significant 
difference; yet there was no significant difference in other tumor sites such as 
cervix, lung, central nervous system, and esophagus. The overall survival 
rate was improved with an overall odds ratio of 1.13. But there was no 
significant chemosensitization or direct bioreductive effect. The main 
confounding factor that may be responsible for this reduced observed benefit 
was less number of patients included. It had been concluded that however, the 
overall results prove that the biological modification of tumor hypoxia 
appears to be very effective, at least in head and neck and bladder carcinoma. 
Future studies related to the hypoxic problem should focus on these sites 
(Overgaard 1994)49. 
For eliminating or modifying the source of radiation resistance, clinical 
trials conducted during the last 40 years have come out with a conclusion that 
this can be achieved by the use of normobaric or hyperbaric oxygen or by 
the use of nitroimidazoles as hypoxic radiation sensitizers. Recent studies 
have also focused on hypoxic cytotoxins, a group of drugs that selectively 
or preferably destroys cells in a hypoxic environment. The review of 
results from 86 randomized trials on modification of tumor hypoxia in 10,108 
patients treated with curative attempted primary radiation therapy alone, 
found a significant improvement in the effect of radiotherapy, with an odds 
ratio of 0.77 for locoregional control and an odds ratio of 0.87 for overall 
survival benefit. But still the hypoxic modification has no impact on general 
clinical practice (Overgaard 2007)45. 
Hypoxic modification by various nitroimidazole group of drugs has 
been explored in a large number of clinical studies. Nine different drugs such 
as misonidazole, metronidazole, benznidazole, desmethylmisonidazole, 
etanidazole, pimonidazole, nimorazole, ornidazole, and RSU 1069, have been 
tested fit for clinical evaluation as hypoxic radiosensitizers. Trials had shown 
a significant relationship between the drug tolerance and expected hypoxic 
modification. The most tolerable drugs among all are found to be 5-
nitroimidazoles, but they had smallest activity. Still, they may be more 
clinically active than others, due to higher tumor/plasma concentrations. 
The extent of benefit obtained with this additional drug cannot be exactly 
measured, since clinically important hypoxia can be observed only indirectly.  
A major breakthrough in the treatment using hypoxic radiosensitizer is 
the report published by Danish head and Neck Cancer Study (DAHANCA) 
Protocol 5-85. Jens Overgaard et al. (1997)50 assessed the efficacy and 
tolerance of nimorazole given as a hypoxic radiosensitizer concurrently with 
primary radiotherapy of invasive carcinoma of the supraglottic larynx and 
pharynx. Among the 422 patients who were randomized between nimorazole 
and placebo arms, the nimorazole group showed a significantly better 
loco-regional control rate than the placebo group (49 versus 33%). A final 
loco-regional control (including surgical salvage) and cancer-related 
deaths were calculated and they too showed similar significant benefit in 
favour of nimorazole. This benefit was also translated into the 10-yr 
overall survival but was not significant. They found that the most important 
prognostic parameters for loco-regional control to be  
1. Positive neck nodes  
2. T3–T4 tumor and 
3. Nimorazole 
The compliance to treatment was at its best and about 98% of the 
patients received the planned dose of radiotherapy. Late radiation-related 
morbidity was same in both the arms and was about 10%. Transient nausea 
and vomiting were the commonest drug-related side-effects. They concluded 
that Nimorazole significantly improves the effect of radiotherapy in 
supraglottic and pharyngeal tumors and can be given without major 
side-effects. 
Sugie C et al., (2005)51 from Japan, reevaluated the radiosensitizing 
effects of sanazole (3-nitrotriazole) and nimorazole (5-nitroimidazole) 
compounds in vitro and in vivo, in comparison with a fluorinated 2-
nitroimidazole derivative KU-2285.  They found no sensitizing effect under 
aerobic conditions at 1 mM in vitro. But in vivo, under hypoxic conditions, 
the sensitizer enhancement ratio (SER) determined at 1% cell survival level 
for sanazole, nimorazole and KU-2285 was 1.55, 1.45 and 1.95, respectively. 
Hence in vivo, all three compounds had significant radiosensitizing effects; 
their effects appeared to decrease in the order of KU-2285, sanazole, and 
nimorazole. It was suggested that sanazole may be more suitable for 
clinical trials than nimorazole. 
Another hypoxic radiosensitizer drug used in clinical trials was 
etanidazole. This drug was used in 374 patients in European Etanidazole 
(ETA) trial and they concluded no advantage of adding the drug to RT. The 
RTOG ETA trial which included 504 patients also showed no global benefit. 
However, under subset analysis positive results were observed in patients 
with early nodal disease (197 patients) (Lee DJ et al. 1996)52. 
Rischin et al. (2010)53 reported on the clinical outcome and the effects 
of tirapazamine in combination with cisplatin and radiation in patients with 
advanced HNSCC; and reported a good response with a 3-year failure-free 
survival rate of 69%. The 3-year local progression-free rate and overall 
survival rate were 88% and 69%, respectively. 
Nimorazole: 
 Nimorazole is a 5-nitroimidazole of same structural class as 
metronidazole. It is the only hypoxic radiosensitizer drug proved to be 
beneficial in phase III randomized clinical trials. Also this drug has the 
advantages of easy administration through oral route and low cost compared 
to other methods of hypoxic modification. Nimorazole was lack of any 
significant side effects except for mild nausea, vomiting, flushing and skin 
rashes. This drug is available in the 500mg tablet formulation. Recommended 
dose in trials was 1.2 gm/m2 BSA and hence they used three, four or five 
tablets for patients with ≤ 1.6 m2 BSA, >1.6 – ≤ 1.9 m2 BSA, > 1.9 m2 BSA, 
respectively. 
 
Misonidazole: 
 This compound mimics the effects of oxygen due to its high electron 
affinity, and thereby fixes the radiation damage and restores the 
radiosensitivity. Nimorazole and misonidazole, both produced significant 
improvements in the clinical outcome. But one major problem with 
misonidazole was peripheral neuropathy, at doses used for radiosensitization. 
Overgaard reported on the randomized controlled trials using misonidazole in 
626 pharynx and larynx carcinoma patients. The tumor control results were 
excellent but 26% of patients developed significant peripheral neuropathy.  
Hypoxia and Radioprotective agents: 
Travis EL (1984) reviewed the role of oxygen in the protection of both 
normal tissues and tumors in vivo by WR-2721 (aminothiol). It is 
hypothesized that sulphydryl compounds by acting on both tumors and 
normal tissues removed the OER differential between them and thus remove 
the natural advantage (radioresistance) of the tumor when treated with 
radiation. He concluded that there was no loss of therapeutic benefit when 
sulphydryl compounds were given along with radiation in conditions with the 
normal tissue being better oxygenated than the tumor, because tumor contains 
hypoxia. 
 
PREVIOUS ARTICLES RELEVENT TO THE PRESENT STUDY 
 Al mamgani A et al. (2009)54 treated LAHNSCC patients, with a 
hypofractionated radiotherapy consisting of 16 fractions of 3.125 Gy 
(Christie Scheme). Most of the patients were male, of which 31% had 
oropharyngeal primaries and 81% were in stage IV disease. They observed an 
enthusiastic overall response rate of 73% (45% CR + 28% PR) and 6% 
stable disease. 21% of patients had progressive disease. A good median 
survival time of 17 months was achieved and 62 patients (40%) survived ≥ 1 
year after RT. The loco-regional control, DFS and OS rates were 62%, 
32% and 40% at 1-year, respectively; and the 3-years figures were 32%, 
14% and 17%, respectively. 45% and 65% of patients developed acute grade 
≥ 3 skin and mucosal toxicities, respectively. 50% gained in weight, 77% 
improved in pain, 47% improved in performance status among the  
patients surviving ≥1 year after RT; and at the end, patients who were 
feeding-tube dependent was 29%. 
Mohamed A. Hassan Metwally et al. (2014)55 retrospectively studied 
the compliance and toxicity profile of 1049 patients with HNSCC, treated in 
Denmark between 1990 and 2013. Their protocol was radical RT (+/- 
chemotherapy) [66 – 70 Gy; 33 – 35 fractions]. All patients received 
concomitant hypoxic radiosensitizer nimorazole 1.2 g/m2 body surface area 
as oral tablets. Those patients, who were treated with accelerated fractionation 
regimen, received a second daily dose of 1g.  The compliance to treatment 
was calculated as the percentage of the initially prescribed dose received by 
the patient. They concluded that the tolerance to nimorazole was fair: 
compliance was 58%. Nausea and vomiting were the major complaints 
recorded. 87% of side effects were due to nausea/vomiting. All side effects 
disappeared when treatment was stopped temporarily and all of them 
were neither severe nor long lasting. Female patients and those aged more 
than 70 years developed more significant nausea/vomiting. In the accelerated 
chemoradiotherapy arm the tolerance was less and more patients had 
nausea/vomiting. They concluded that nimorazole had tolerable acute, but 
neither persistent nor late, toxicity and can be safely administered with 
chemotherapy and different radiotherapy fractionation schedules. 
Meta-analysis of 32 randomized clinical trials on the modification of 
tumor hypoxia, included 4805 patients with HNSCC treated under 5 trials of 
normobaric oxygen or carbogen breathing, 9 trials of hyperbaric oxygen 
(HBO), 17 trials of hypoxic radiosensitizers and 1 trial on HBO and 
radiosensitizer together. The overall hypoxic modification of radiotherapy 
produced a significant improved therapeutic benefit for all types of 
modifications. There was a very little advantage in the reduction of risk of 
distant metastasis. The important observation was that there was no 
significant change in the radiation related late complications. Different 
fractionation schedules, including large doses per fraction, have been 
used in these trials, which were thought to result in relatively more 
hypoxia and hence greater benefit. However, analysis of HNSCC trials 
using conventional fractionation only, showed that the significant effect of 
hypoxic modification was maintained (Overgaard 2011)56. 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS and OBJECTIVES of present study 
Primary Objective: 
 To assess the immediate loco regional response rates of locally 
advanced head and neck squamous cell carcinoma after 6 weeks of 
treatment protocol 
 To assess the degree of symptom relief 
Secondary Objective: 
 To assess the acute toxicity of the treatment 
 
INCLUSION CRITERIA 
• Biopsy proven cases of SCCHN 
• Primary tumor sites: oropharynx, hypopharynx, supraglottic larynx 
• Non metastatic disease 
• Unresectable and locoregionally advanced cases  
• Stage IV A with performance status ECOG 3 
• Stage IV B with performance status ECOG 2 or 3 
• Age: 18-70 
• Blood counts: TC > 4*10³/cu. mm, Platelet count > 100*10³/cu. mm, 
Hb. > 10 gm% 
• Signed informed consent prior to initiation of protocol specific 
procedures 
 
EXCLUSION CRITERIA 
• Primaries of oral cavity, nasopharynx, nasal cavity and para nasal 
sinuses, salivary and thyroid glands 
• Uncontrolled medical comorbidities, connective tissue disorders 
• Prior chemotherapy or radiotherapy 
• Second primary malignancies in any site 
• Recurrent or relapsed disease 
 
PRE-TREATMENT WORK UP AND GENERAL MEASURES 
 History and physical examination (with complete Head and Neck 
examination) 
 Base line symptom assessment using symptom assessment scale (SAS). 
 ENT examination and OGD scopy, as clinically indicated 
 Biopsy of the primary site 
 FNAC from the enlarged lymph node  
 Baseline complete hemogram 
 Blood grouping and typing 
 Renal function tests 
 Contrast enhanced computed tomography (CECT) of the primary and 
neck, from base of skull to root of neck 
 Chest X-ray PA view- digital 
 HIV – 1&2,  
 HBsAg, Anti HCVAb, 
 Dental evaluation 
 Smoking and alcohol cessation counselling 
 Nutrition, Speech and Swallowing evaluation 
 Prophylactic feeding tube placement, if indicated 
 
 
 
MATERIALS AND METHODS 
30 patients presenting to our department who were eligible to be 
included as per the study protocol, were selected. Patients were enrolled into 
the study after obtaining approval from the Institutional Ethics Committee for 
conducting this study. Information sheet on the study protocol was given to 
all patients and the study was explained briefly to them. After that oral and 
written informed consents were obtained from all the patients before 
including in the study. 
After the pre-treatment work up, patient preparation and dental 
prophylaxis, patients were treated with external beam radiotherapy to the 
primary and neck nodes, 48 Gy in 3 Gy# over 3.2 weeks, 5# per week, using 
Cobalt-60 teletherapy machine (Theratron Phoenix) in palliative intent. In 
addition to this, patients received Tab.Nimorazole 1.2 gm/m² daily (only on 
RT days), orally, 90 min before radiation. Dose of Nimorazole is based on 
body surface area: ≤1.5 m² BSA - 1500mg (3*500mg tablets), >1.5 m² BSA - 
2000mg (4*500mg tablets). 
Response evaluation was done using RECIST criteria. The pre-
treatment volumes of the primary and nodal tumor were recorded and 
compared with post-treatment status. The symptoms experienced by the 
patients at the baseline, at the end of treatment and 6 weeks after treatment 
were recorded using symptom assessment scale. The common side effects of 
treatment protocol such as nausea, vomiting, flushing and rashes and acute 
radiation induced toxicities were looked for while under treatment, at the end 
of treatment and 6 weeks after treatment. 
Patient preparation and Prevention of toxicities: 
Patients who were found to be anemic were given blood transfusion. 
Local infection was controlled with antibiotics. Before starting antibiotics, 
pus culture and sensitivity was ordered, when clinically indicated. Patients 
were given counselling on adequate and nutritious food intake by a dietician. 
Patients having significant weight loss, dysphagia or those who are at risk of 
developing dysphagia were advised Naso Gastric tube feeds.  
Those with poor oral hygiene and extensive stains of teeth were 
referred for scaling and oral hygiene improvement. Those patients with teeth 
that reside within the high dose radiation volume that demonstrate advanced 
caries, significant periodontal disease, etc., were referred for dental 
prophylaxis and extraction. All those who underwent extraction were given 
prophylactic antibiotics. OPG was taken if clinically indicated and any 
infected retained root tips or symptomatic cysts if present, were dealt with. A 
gap of 2 weeks was allowed for the extractions to heal, before the start of 
radiotherapy. 
Oral care also includes prevention and treatment of mucositis and 
pharyngitis. They were advised to use gargling with soda bicarbonate 
dissolved in water, about 4 times daily, especially after any food intake. 
Candidiasis was treated with topical clotrimazole oral paint for 2 weeks; if the 
lesions are not resolving then oral fluconazole tablets 150 mg OD were given 
for 10-14 days. 
Nutritional support: 
Most of the HNC patients lose weight not only due to cancer but also 
treatment related toxicities. So nutrition management is very important to 
prevent/ reduce the treatment related complication and thereby improve the 
therapeutic outcome of treatment. 
All the patients were motivated to take adequate nutrition to prevent 
excessive weight loss. Those patients with significant weight loss (>5% of 
weight in the month before / >10% of weight in the previous 6 months) were 
advised prophylactic nasogastric tube or PEG (percutaneous endoscopic 
gastrostomy) placement. In extreme cases where nutritional support by enteral 
route was not possible or not adequate, parenteral (intravenous) nutritional 
support was given. 
Specific meal plans were developed for individual patients. The meal 
plans were designed so that they were as close to the normal diet as possible. 
The patient’s weight was checked serially every week, to evaluate the 
patient’s nutritional intake. Depending on the weight the meal plans were 
revised, if needed. The meal plans were designed with the idea of the 
increased caloric and protein requirements of the patient for tissue 
regeneration. 
From the third week of treatment, side effects of radiation will start and 
hence the patients were advised to take liquid diet. The radiation induced 
dysphagia and mucositis were mainly due to pharyngitis and laryngitis. Also 
during this stage patients start developing  xerostomia, which adds up to the 
difficulty in swallowing solid foods; also making the foods to stick to mucosa 
and induces vomiting.  The patients were advised to take a sip of water with 
each bolus of food; plenty of fresh fruit juices like apple and guava will also 
help and citrus fruits like lemon and Mozambique may be avoided. A special 
home- made high protein food using banana, egg and milk, or protein 
formulations were advised twice daily. 
Smoking cessation: 
Smoking and alcohol cessation counselling were advised, if found to be 
current smokers advised to quit smoking and if they were past smokers 
advised to remain so. 
Screening for depression: 
A brief screening for depression was done and counselling +/- drug 
therapy was advised. Psychiatrist advice was obtained when needed. 
 
Radiotherapy Technique: 
Radiotherapy was delivered in right and left lateral parallel opposed 
portals and the dose was prescribed to the midline with equal weightage; with 
patient in left and right lateral positions; with a telecobalt Theratron Phoenix 
machine with 2D technique; in 300cGy per fraction, 5 fractions per week, up 
to 16#. Treatment volume included the primary tumor site and level II-VB 
neck nodal regions. Level IB was included in involved cases. 1 cm margin for 
setup error was added. A bolus was used when skin infiltration both by the 
tumor or by the lymph nodal mass, was present; and also for all ulcerated 
lymph nodes.  
 In cases with N3 neck nodes on one side with clinically N0 on the 
other side, a 2:1 weightage will be given in RT dose distribution. Offcording 
is done after 30Gy. Many of the posteriorly placed nodes interfered with usual 
off-cording. Hence off-cording was individualised to each patient as per the 
location of the nodal mass. 
PRE TREATMENT ASSESSMENT OF SYMPTOMS 
The most common distressing symptoms experienced by the patients 
were assessed at the start of treatment, during and after treatment. There are 
many systems to assess this. We used the 11 point symptom assessment scale 
(SAS). 
Symptom assessment scale 
The SAS describes the patient’s level of distress relating to individual 
physical symptoms. The instrument was very much patient-friendly and 
designed to be a patient rated tool. 
How to assess? 
Patient can himself rate the degree of distress for each of their 
symptom. If patient is not able to do so, family members/ attenders are asked 
to rate the degree of distress. But it is always better if the patients rate their 
own symptoms for accuracy and consistency. 
Figure- 4: 11-point numeric scale 
11-point numeric scale was used to assess the symptom. 
 
If there is no Symptom, rating was given as ‘0’. If Symptoms present 
rating was given from 1 to 10. 
All the patients were given the information that, 
A score of 0: no symptoms 
A score of 1: very minimal/least possible distress  
A score of 10: the worst possible distress. 
Assessment was done at the baseline then every week after starting the 
treatment and at 6 weeks post treatment. 
ASSESSMENT IN BETWEEN TREATMENT 
 Pain and other symptoms experienced by the patients before treatment 
were continued to be assessed while on treatment, using SAS. 
Toxicity of radiotherapy: the following toxicities were assessed for 
their presence and severity, at the end of every week of treatment, using 
RTOG acute toxicity grading. 
 Skin reactions 
 Mucositis 
 Xerostomia  
 Laryngitis 
 Pharyngitis 
 Hb level 
 Complete blood counts 
Toxicity of Nimorazole: the following toxicities were assessed for the 
presence and severity, at the end of every week of treatment, using Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03. 
 Nausea / Vomiting 
 Flushing 
 Skin rashes 
SUPPORTIVE CARE AND TOXICITY MANAGEMENT 
Along with the management of the treatment related toxicities, patients 
were given supportive care to tackle their other symptoms due to their 
disease. Few among them were: 
• Management of cancer pain, vomiting, cancer related anemia, 
fatigue and distress. 
• Prevention and treatment of infections due to cancer.  
• Palliative care and nutrition support. 
All patients were registered in palliative care OP department. After 
assessing the patients completely, Tab.morphine 5mg fourth hourly was given 
along with anti depressants, sedatives and laxatives, for those who needed. 
They were instructed to take morphine ‘by the clock’ method and not ‘by the 
pain’. Patients taking morphine were given syrup liquid paraffin or bisacodyl 
tablets and advised about the possible side effect of constipation, and hence 
the need for plenty of oral fluids and fiber intake. All the patients were 
reviewed once in a week for the degree of symptom relief. 
Vitamin B-complex and vitamin C tablets were given to all. Packed cell 
transfusion was given to the patients whose haemoglobin levels falls to 
<10gm%. All patients were given prophylactic vitamin B12 injection, once 
weekly during treatment.  Proper cleaning and dressing of the wound was 
done for ulcerated, fungated nodes and primaries. Such patients were given 
higher antibiotics coverage for 7 to 10 days.  
The nausea and vomiting were managed by antiemetics and steroids; 
Inj.Ondansetron 8 mg i.v. twice daily and Inj. Dexamethasone 4mg OD was 
given. Those patients who cannot take adequate oral fluids were also given 
i.v. fluids to prevent dehydration.  
For the prevention and treatment of mucositis all patients were advised 
to maintain good oral hygiene and gargling 4-6 times a day using soda 
bicarbonate dissolved in water. Patients were also instructed to apply honey 
15 minutes prior to the radiation, 15 minutes after radiation and 12 hours after 
radiation. If the patients develop mucositis, they were treated by using 
analgesics (NSAIDS), low dose steroids, placentrex injection and if severe, 
prophylactic antibiotics. NSAIDS used was Diclofenac sodium tablets 50 mg 
twice daily. The steroid used was dexamethasone 4 mg IV twice daily if the 
patients developed grade III mucosities. All patients with grade III mucositis 
were treated with antibiotic, cephalexin 500 mg four times daily.  
NSAIDS and antitussives were given for grade II pharyngitis and 
laryngitis. Steroids were included in the management of all grade III 
toxicities. Opioid analgesic, inj.tramadol was given for all grade III mucositis, 
pharyngitis and laryngitis. Candidiasis was treated with clotrimazole mouth 
paint. 
 
RESPONSE EVALUATION: 
Patients were evaluated after 6 weeks of the treatment protocol. 
Subjective response: 
Degree of symptomatic relief was assessed using symptom assessment 
scale. 
The patients were grouped based on their degree of relief in symptoms, 
into three viz., those having <25%, 25 - <50%, ≥50% relief. Those with ≥50% 
improvement was said to have significant relief of symptoms57. 
 
 
 
Objective response: 
Response in the Primary and Nodal tumor was assessed clinically and 
radiologically. Patients were asked to take a CT scan of the primary and neck 
(plain and contrast). The response was categorized using RECIST criteria: 
 Complete response (CR) – absence of residual tumor at any site after 
treatment 
 Partial response (PR) - ≥30% decrease in the size of the tumor from 
baseline 
 Stable disease (SD): Neither sufficient shrinkage nor sufficient increase 
in size 
 Progressive disease (PD): 20% increase in size from base line 
The toxicities to the treatment such as radiation induced morbidities 
and toxicities specific to nimorazole were assessed at the end of 6 weeks. 
FOLLOW UP OF PATIENTS  
Patients who completed the treatment protocol were asked to review 
once in 2 weeks to assess and treat the toxicities, if any. After 6 weeks, they 
were asked to come for assessing the response to the treatment. All patients 
were advised to take a CT scan of the primary and neck with contrast. Patients 
were followed up every month thereafter. 
RESULTS 
AGE DISTRIBUTION 
Totally 30 patients were enrolled in the study. Eligible age limit for the 
study was from 18 to 70 years of age. The age of the patients ranged from 52 
to 70 years. The median age of the patients included in the study was 65 
years. 
Table - 2 
AGE GROUP 
(in Years) 
No. OF PATIENTS PERCENTAGE (%) 
51 – 60     13 43.3 
61 – 70     17 56.7 
 
13 patients were in the age group of 51 – 60 and 17 were in the age 
group of 61-70. Age distribution analysis of the sample showed that, most of 
the patients were in age the group of above 60 years. 
SEX DISTRIBUTION 
All the 30 patients were males. This skewed selection towards the male 
gender was probably due to the increased exposure of carcinogens in the 
males than in females. 
SITE DISTRIBUTION: 
Among the 30 patients, primary site of the disease was oropharynx in 
15 patients, hypopharynx in 9 and supraglottic larynx in 6.  
Table -3 
Site No.of.patients Percentage (%) 
Oropharynx   15 50.0 
Hypopharynx    9 30.0 
Supraglottic Larynx    6 20.0 
 
The site wise distribution of the cancer patients included in the study 
showed, majority of the tumors were from oropharynx. 
SUBSITE INVOLVEMENT: 
OROPHARYNX- SUBSITE DISTRIBUTION 
Table-4 
Sub site No.of.patients 
Tonsillar fossa  9 
Posterior 1/3rd tongue 4 
Soft palate  2 
 
Among the 15 cancer of the oropharynx patients, tonsillar fossa in 9, 
posterior one third tongue in 4 and the soft palate in 2 were the principal 
subsites involved. 
HYPO PHARYNX-SUB SITE DISTRIBUTION 
Table- 5 
Sub site No.of.patients 
Pyriform fossa  5 
Posterior pharyngeal wall  3 
Post cricoid region  1 
 
Among the 9 hypopharyngeal cancers patients, pyriform fossa in 5, 
posterior pharyngeal wall in 3 and post cricoid region in 1 were the principal 
subsites involved. 
LARYNX- SUB SITE DISTRIBUTION 
Six supraglottic cancer patients were included in the study. 
PRIMARY TUMOR CHARECTERISTICS 
Majority of the patients were in T3 and T4 stage.  
 
Table -6; T STAGE 
T stage No.of.patients 
T1 3 
T2 4 
T3 10 
T4a 10 
T4b 3 
 
Among the 30 patients, 3 were in T1, 4 were in T2, 10 were in T3, 10 
were in T4a and 3 were in T4b stages, respectively. 
Table -7; N stage distribution 
N stage  No.of.patients 
N2b 6 
N2c 4 
N3 20 
 
Majority of the patients were in N3 stage. Among the 30 patients, 20 
were in N3, 6 were in N2b and 4 were in N2c stages, respectively. Out of 
them 6 patients presented with ulcerated nodes. 
STAGE GROUPING 
Table – 8 
Stage group No.of.patients 
Stage IVA 9 
Stage IV B 21 
 
Most of the patients were in stage group IV B. 21 out of 30 patients 
was in stage group IV B and 9 were in stage group IV A. 
DIFFERENTIATION 
Majority of the patients had moderately differentiated tumors. Among 
the 30 patients 24 had moderately differentiated, 4 had poorly differentiated 
and 2 had well differentiated tumors. 
Table - 9 
Differentiation No.of.patients (%) 
Well differentiated  2 (26.7%) 
Moderately differentiated  24 (80%) 
Poorly differentiated  4 (13.3%) 
 
 
SYMPTOMS AT PRESENTATION 
Table -10 
Symptoms No. of cases who had that symptom 
Local pain 25 (83%) 
Dysphagia 18 (60%) 
Cough 10 (33%) 
Otalgia 15 (50%) 
Dyspnoea 4 (13%) 
Voice change 5 (16%) 
Insomnia 23 (76%) 
 
Pain was the most common complaint, and was reported by 83% of the 
patients. Next common presenting somatic complaints were dysphagia and 
otalgia, in 60% and 50% of patients, respectively. Insomnia was found in 76% 
of patients. Other symptoms to note with, in a few at presentation were 
dyspnoea, cough and voice change. Few of the patients had all the above said 
symptoms in a mixed form, while others had half or more than half of the 
above mentioned symptoms.  
 
 
SYMPTOM ASSESSMENT AFTER TREATMENT 
 Those with significant improvement (≥50%) in their symptoms were 
taken into account. 
• Local pain improved in 20 out of 25 (80%) 
• Dysphagia improved in 12 out of 18 (66%) 
• Otalgia improved in 12 out of 15 (80%) 
All together the treatment protocol resulted in good symptom relief and 
hence a better QOL in a good proportion of patients. 
RESPONSE ASSESSMENT IN TUMOR 
Table – 11 (n=30) 
Response  No.of.patients 
Complete response (CR) 6 (20%) 
Partial response (PR) 17 (56.7%) 
Static response (SR)  7 (23.3%) 
Progressive disease (PD)  0 (0%) 
 
Most of the patients achieved a partial response with this treatment 
protocol. About 17 patients had a partial response, contributing to a good 
number of 56.7% response. Although palliation was the main aim of the 
study, fortunate results were complete response in 6 patients, which accounts 
to 20% of patients. None had progression in the disease or tumor burden, 
during the 6 week response assessment. 
OVERALL RESPONSE 
 Among 30 patients 23 (6 CR+ 17 PR) achieved some form of response 
in the tumor which yields an overall response rate of 76.7%. 
STAGE GROUP WISE TUMOR RESPONSE ASSESSMENT 
Table – 12 
Stage group CR PR SR PD 
IV A 6 3 0 0 
IV B 0 14 7 0 
 
The complete response which was obtained in 6 patients was solely 
from the stage group IV A. Most of the patients from stage group IV B 
attained partial response. None of the patients in any group had progressive 
disease. 
 
 
RADIATION RELATED ACUTE TOXICITY ASSESSMENT 
None of the patients developed any grade 4 acute radiation toxicities. 
Mucositis: 
Most of the patients developed grade 2 mucositis after about 2 weeks of 
treatment. Grade 3 mucositis was seen in 12 patients. In them treatment was 
suspended to allow for the resolution of mucositis before proceeding with 
further radiation. Benzydamine mouthwash, inj.placentrex and opioid 
analgesics were given to hasten the recovery and improve the patient’s 
tolerance. 
Dysphagia: 
 Most of the patients had grade 2 dysphagia. 14 patients developed 
grade 3 pharyngitis. Treatment was temporarily suspended in them. They 
were given opioid analgesics in addition to NSAIDs and adjuvant analgesics. 
Xylocaine viscus and low dose dexamethasone were added. 
Dermatitis: 
None developed grade 2 or grade 3 skin reactions. Most of them 
developed grade 1 reaction which was treated with Cansafe ointment, an 
ayurvedic preparation specially made for radiation induced dermatitis. 
 
Salivary gland toxicity: 
Grade 2 salivary gland reaction was seen in 10 patients. Almost all 
other patients developed grade 1 toxicity. But none had acute necrosis of the 
salivary gland. All of those who had any degree of xerostomia were 
prescribed artificial salivary supplements – mouth gargles or mouth spray. 
Laryngitis: 
Almost all patients had minimal hoarseness of voice and 8 patients 
developed grade 3 laryngitis in the form of otalgia and opioid analgesics were 
added. 
Haematological toxicity 
None of the patients had thrombocytopenia.  
None of the patients developed significant haematological toxicities, 
except for grade 1 anemia, leucopenia and neutropenia. Grade 1 anemia was 
seen particularly in patients who had low haemoglobin levels prior to starting 
treatment and for which blood transfusions were given previously, and they 
were given blood transfusions again. 
 
 
 
ASSESSMENT OF TOXICITIES SPECIFIC TO NIMORAZOLE: 
None of the patients developed skin rashes or flushing.  
NAUSEA 
None of the patients developed grade 3 toxicity of nausea. Grade 2 
nausea was seen in 4 patients. Grade 1 nausea was seen in some of the 
patients.  
Table - 16 
Nausea No.of  cases 
Grade 1  12 
Grade 2   4 
Grade 3  0 
 
Grade 1 vomiting was seen in 4 patients. None had significant higher 
grades of vomiting. 
DOSE REDUCTION: 
 4 patients who developed significant grade 2 nausea had dose reduction 
in nimorazole. They received 1000 mg instead of 1500 mg per day after 
developing toxicities, till the end of their treatment. 
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DISCUSSION 
Majority of the HNSCC cases (60%-80%) in India are presented in 
advanced stage. Radical treatment is not successful in all of these patients 
because of poor performance status and unresectability. These advanced and 
unresectable cases need palliative treatment and/or best supportive care. There 
is no general consensus regarding palliative schedule in SCCHN. Few 
researchers have evaluated conventional fractionated radiotherapy versus 
hypofractionated palliative radio therapy schedules for patients with locally 
recurrent or advanced HNC. They compared 60 Gy to 70Gy over 6 to 7 weeks 
with 40 Gy to 48 Gy over 3 to 4 weeks in stages III and IV surgically 
unresectable SCCHN. No difference was observed in terms of tumor control, 
acute toxicity and chronic toxicity. 
Most of the institutions believe that larger tumors will respond very 
poorly to conventional fractions of radiotherapy. The general consensus for 
treating bulky solid tumors of the head and neck with radiotherapy is the use 
of hypofractionated regimens. The institutional protocol for this in our 
institute was 48 Gy in 16 fractions of 3 Gy each. Another reason to choose 
such regimen was the patient load for treatment using EBRT, especiallly in 
government institutions, so that treatment can be completed soon. 
In patients deemed to be incurable, the first aim of any treatment will 
be improving the Quality of Life, which can be achieved with good symptom 
control and to some extent by achieving at least some response in the tumor. 
Even a minimal response in the tumor could add up to improvement in 
symptom control. At the same time there should not be any added toxicities. 
Keeping these things in mind, what sort of further modifications in the 
treatment can produce such benefits, should be thought of. Hence logically 
thinking, improvement in the response at the tumor should also be our goal 
even in a palliative setting. 
Patients with poor performance status are generally unfit to receive a 
radical regimen of chemotherapy both 3-weekly and weekly. Even the 
reduced dose of weekly chemotherapy will produce some toxicities such as 
mucositis and myelosuppression, which will land up in increased treatment 
breaks and more importantly reduced and unacceptable Quality of Life. But as 
per the guidelines even in LASCCHN cure should be the primary intention in 
patients with good PS. In patients with poor PS, the treatment should be 
individualised and hence in this study we safely avoided any chemotherapy to 
patients along with RT. 
Hypoxia and neovascularisation are interdependent. The findings of 
diffusion-limited hypoxia in human lung cancer are based on the evidence of 
the presence of necrotic tissue beyond 180µ radius from the capillary margin. 
Larger and bulky tumors have less neovascularisation and hence more 
hypoxia. This along with its countertpart, perfusion-limited hypoxia plays a 
vital role in making the cancer cells more locally aggressive, metastatic, and 
resistant to therapy. Hence the hypoxic modification becomes a prime 
thought, at least in large volume tumors. 
Hypoxic modification of radiotherapy has shown clinical benefit in the 
treatment of HNSCC and to some extent in uterine cervix carcinoma. 
Nimorazole has been adapted for routine clinical use in head and neck cancer 
patients in Denmark since 1990, due to the outcome of the DAHANCA 2 and 
DAHANCA 5 studies which both demonstrated the benefit of hypoxic 
modification in supraglottic larynx and pharynx cancers. Nimorazole is a 5-
nitroimidazole compound used as hypoxic radiosensitizer. Its high electron 
affinity makes the drug mimic the effect of oxygen in making the tumor more 
radiosensitive. Though it is less potent than misonidazole its high 
tumor/plasma ratio brings a similar radiosensitization; and also it lacks the 
neurological toxicity. 
The main advantages with 5-nitroimidazole group of drugs, especially 
nimorazole are ease of administration through oral route, cost effectiveness, 
very less toxicities and easily manageable toxicities and hence good patient 
compliance, and finally easy titration of the dose when toxicities occur. 
In the DAHANCA-5 study 51% of the patients achieved the planned 
drug treatment. The current study shows that the compliance of patients 
with the full prescribed dose was 87% (4 patients had dose reduction due 
to side effects). When nimorazole was added to CHART regimen, about 22% 
of patients developed nausea/vomiting. Few trials added cisplatin with 
nimorazole and RT. In these it was difficult to assess retrospectively whether 
the nausea/vomiting were really due to nimorazole. Few studies have 
demonstrated it to be a fairly tolerable drug. 
The patients under ‘Christie Scheme’ hypofractionated radiotherapy 
were treated using 16 fractions of 3.125 Gy. The BED equivalent of this was 
65.6 Gy10 and the EQD2 was 54.7 Gy and in the present study they were 62.4 
Gy10 and 52.0 Gy respectively, which were almost similar. Most of them were 
under stage IV. They observed an overall response rate of 73%. In the present 
study we observed an overall response rate of 76.7%, which may be attributed 
to the addition of hypoxic radiosensitizer. 
In this present study also, the side effects of nimorazole were in 
very few patients only and they were neither severe and nor long lasting. 
Most patients tolerated well. Along with the good symptom control, 
partial to complete response was attained in the tumor in many patients. 
 
 
 
 
Limitations of the study 
In the present study patients were not followed up for long term to 
arrive at the conclusions such as the duration of symptom relief, loco regional 
control rate and disease free survival in those who achieved complete 
response, distant failure rate, progression free survival in those who achieved 
partial and static responses and as a whole, the overall survival of the patients. 
Larger sample size of patients is needed to arrive at a definitive 
conclusion on the basis of achieving statistical significance. 
Radiotherapy dose of 48 Gy achieved an EQD2 of 52.0 Gy and further 
dose escalation can be tried in those patients with good tolerance to achieve 
an EQD2 of at least 60 Gy with the intent of increasing the response in the 
tumor, thereby achieving better symptom control and hence better QoL. 
 
 
 
 
 
 
 
CONCLUSION 
In patients with LAHNSCC palliative radiotherapy along with 
Nimorazole effectively restrained the growth of tumor and in few produced 
cure, achieved good palliation of symptoms and thereby increased the quality 
of life of patients without any added toxicities, in the short run. Yet long term 
studies are needed to comment more on this. 
Also, this study is trying to strike a balance between economic burden, 
treatment time and hospital stay and patient load on the machines.  
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ANNEXURE I 
RTOG ACUTE TOXICITY GRADING 
Grade 0 1 2 3 4 
MUCOSITIS No 
change 
Injection / 
Mild pain not 
requiring 
analgesic 
Patchy 
mucositis; 
Moderate 
pain needs 
analgesia 
Confluent 
mucositis; 
Severe pain, 
needs 
morphine 
Ulceration, 
hemorrhage 
and Necrosis 
DERMATITIS No 
Change 
Follicular, 
faint, dull 
erythema/ 
epilation/ 
desquamation 
Tender, 
bright patchy 
moist 
desquamation 
Confluent 
moist 
desquamation 
Ulceration, 
hemorrhage 
and Necrosis 
SALIVARY 
GLAND 
No 
Change 
Mild dryness 
/ Altered 
taste 
Moderate to 
complete 
dryness 
 
----- 
Necrosis 
PHARYNX No 
Change 
Mild 
dysphagia 
requiring 
analgesics 
Moderate 
dysphagia 
requires 
narcotics. 
Liquid diet 
Requires IV 
fluids or NG 
tube 
Ulceration, 
perforation 
and fistula 
LARYNX No 
Change 
Mild 
Hoarseness, 
Cough 
doesn,t need 
treatment 
Persistent 
hoarseness, 
Cough 
requiring 
antitussive 
Whispered 
speech, throat 
pain 
requiring 
narcotics 
Dyspnea/ 
stridor, 
hemoptysis 
with 
tracheostomy 
 
 
 
 
HEMATOLOGICAL TOXICITY 
 
Grade  0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000) 
>=4.0 3.0 - <4.0 2.0 - <3.0 1.0 - <2.0 <1.0 
PLATELETS (X 
1000) 
>=100 75 - <100 50 - <75 25 - <50 <25 or 
spontaneous 
bleeding 
NEUTROPHILS >=1.9 1.5 - <1.9 1.0 - <1.5 0.5 - <1.0 <0.5 or sepsis 
HEMOGLOBIN 
(GM %) 
>11 11-9.5 <9.5 - 7.5 <7.5 - 5.0 - 
 
 
 
 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
(CTCAE) version 4.03 
Definition of nausea: A disorder characterized by a queasy sensation and/or the urge to 
vomit. 
Definition of vomiting: A disorder characterized by the reflexive act of ejecting the 
contents of the stomach through the mouth. 
Definition of flushing: A disorder characterized by episodic reddening of the face. 
 
 
Adverse 
Event 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Nausea Loss of appetite 
without  
alteration in 
eating habits 
 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration or 
malnutrition 
Inadequate oral 
caloric or fluid 
intake; tube 
feeding, TPN, or 
hospitalization 
indicated 
- - 
Vomiting 1 - 2 episodes 
(separated by 5 
minutes) in 24 
hrs 
 
3 - 5 episodes 
(separated by 
5 minutes) in 
24 hrs 
 
>=6 episodes 
(separated by 5 
minutes) in 24 
hrs; tube 
feeding, TPN or 
hospitalization 
indicated 
Life-
threatening 
consequences; 
urgent 
intervention 
indicated 
 
Death 
 
Flushing Asymptomatic; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicated 
 
Moderate 
symptoms; 
medical 
intervention 
indicated; 
limiting 
instrumental 
ADL 
Symptomatic, 
associated with 
hypotension 
and/or 
tachycardia; 
limiting self care 
ADL 
  
 
 
 
 
ANNEXURE II 
INFORMATION TO PARTICIPANTS 
Title: “Palliative radiotherapy along with Nimorazole as hypoxic radio sensitizer in locally 
advanced head and neck squamous cell carcinoma” 
Principle Investigator:  Dr. Ragavendra A. 
Name of Participant: 
Site: Department of Radiotherapy, Madras Medical College & RGGGH, Chennai-3 
You are invited to take part in this research/ study/procedure. The information in this 
document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries. 
What is the purpose of this study? The incidence of head and neck cancers has been 
increasing worldwide. As many cases present only in advanced stage, curative surgery or 
curative chemo radiation is not possible. Among the many palliative treatment options 
available, with our treatment methodology we are aiming to give a better palliation for the 
disease by achieving a better immediate loco regional response, better symptom control 
and less treatment related toxicity. 
We have obtained permission from the Institutional Ethics Committee. 
The study design:  Single arm Prospective study. 
Study Procedures: Patients will need to undergo blood investigations, CT scan neck, X-
ray chest, dental prophylaxis and Smoking cessation counselling, if smoker, which were 
done routinely in all head and neck cancer patients. These tests are essential to assess the 
status of the disease. Patients are treated with palliative radiotherapy in hypofractionated 
regimen over 3 weeks along with tablet nimorazole daily. This is followed by assessment 
for toxicity and response and after 6 weeks. Patients will undergo clinical examination, 
laryngoscopy and CT scan neck for this. These tests are essential to assess the efficacy of 
treatment. 
Possible risks to you: None greater than patients receiving standard radiotherapy. Possible 
benefits to you: Better response at the tumor and less toxicity from treatment. 
Possible benefits to other people: The results of the research may provide benefits to the 
society in terms of advancement of medical knowledge and/or therapeutic benefit to future 
patients. 
Confidentiality of the information obtained from you: You have the right to 
confidentiality regarding the privacy of your medical information (personal details, results 
of physical examinations, investigations, and your medical history). By signing this 
document, you will be allowing the research team investigators, other study personnel, 
sponsors, Institutional Ethics Committee and any person or agency required by law like the 
Drug Controller General of India to view your data, if required. The information from this 
study, if published in scientific journals or presented at scientific meetings, will not reveal 
your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and you 
will not lose any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during the course of the study without giving any reasons. You 
will still continue to receive the standard treatment if you decide so. However, it is 
advisable that you talk to the research team prior to stopping the treatment/discontinuing of 
procedures etc. 
 
Signature of Investigator                                            Signature of Participant                                                            
Date                                                                            Date 
 
 
 
 
ANNEXURE III 
 
INFORMED CONSENT FORM 
 
TITLE OF THE STUDY: “Palliative radiotherapy along with Nimorazole as hypoxic radio 
sensitizer in locally advanced head and neck squamous cell carcinoma” 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPLE INVESTIGATOR: Dr.Ragavendra A. 
NAME OF THE INSTITUTION:  Madras Medical College 
 
I, _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in this study 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in 
the past 12 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms.* 
8. I have not participated in any research study within the past 12month(s). * 
9. I agree to undergo complete blood count, renal and liver function test, CT scan neck 
and X-ray chest 
10. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital.* 
11. I am also aware that the investigator may terminate my participation in the study at any 
time, for any reason, without my consent.* 
12. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
13. I have understood that my identity will be kept confidential, if my data are publicly 
presented. 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, and I will be given a copy of this consent 
document. 
 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name ________________    Signature_________________    Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________    Signature_________________    Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent 
Name ________________    Signature_________________    Date________________ 
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